PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma
Expression and Clinical Significance of PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma
1 other identifier
observational
104
1 country
1
Brief Summary
The prognostic value of programmed death-ligand 1 (PD-L1) and BRAF expression in nasopharyngeal carcinoma (NPC) is not well-defined. In this study the investigators investigated alterations in PD-L1, BRAF and EGFR by using immunohistochemistry analysis in a cohort of consecutively enrolled NPC patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2017
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedFirst Submitted
Initial submission to the registry
June 14, 2019
CompletedFirst Posted
Study publicly available on registry
June 18, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2019
CompletedSeptember 2, 2020
September 1, 2020
2.9 years
June 14, 2019
September 1, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Response rate
Efficacy after radiation
Followed up with 12 months after last patient in
Secondary Outcomes (1)
Survival rate
Followed up with 12 months after last patient in
Study Arms (1)
NPC patients
Consecutive patients who were pathologically diagnosed with NPC and for whom fresh-frozen tissue samples were available were included.
Interventions
Consecutive patients who were pathologically diagnosed with NPC and treated with radiation at the Kiang Wu Hospital.
Eligibility Criteria
Consecutive patients who were pathologically diagnosed with NPC between 2006 and December 2010 at the Kiang Wu Hospital (Macau, SAR China) and for whom fresh-frozen tissue samples were available were included.
You may qualify if:
- Above 18 years of age
- Locally advanced (stage IIIB) or metastatic (stage IV) NPC
- Fresh-frozen tissue samples were available were included
- After treatment with curative surgery or radiotherapy in Macau
- With follow up data were available
You may not qualify if:
- Enrolment in studies that prohibit any participation in this observational study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Kiang Wu Hospital
Macao, 999078, China
Related Publications (1)
Cao Y, Chan KI, Xiao G, Chen Y, Qiu X, Hao H, Mak SC, Lin T. Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma. BMC Cancer. 2019 Oct 29;19(1):1022. doi: 10.1186/s12885-019-6276-y.
PMID: 31664962DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yabing Cao, MD; PhD
Kiang Wu Hospital, Department of Oncology
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 14, 2019
First Posted
June 18, 2019
Study Start
January 1, 2017
Primary Completion
December 1, 2019
Study Completion
December 30, 2019
Last Updated
September 2, 2020
Record last verified: 2020-09